Forty Seven Inc. Announces Publication in The New England Journal of Medicine of 5F9 Phase 1b Clinical Data in Non-Hodgkin’s Lymphoma (NHL)
Publication Reaffirms Therapeutic Potential of CD47 Inhibition as Novel Approach to Treating Cancer
Enrollment Ongoing in Phase 2 Portion of Clinical Trial Evaluating 5F9 in Combination with Rituximab for Patients with Relapsed/Refractory NHL
“While newer therapies have shown robust activity in r/r
The NEJM publication, “CD47 Blockade by Hu5F9-G4 combined with Rituximab in Non-Hodgkin’s Lymphoma,” includes data from the Phase 1b portion of Forty Seven’s ongoing Phase 1b/2 clinical trial, which were originally presented at the 2018
Forty Seven is currently evaluating 5F9 in the Phase 2 portion of this Phase 1b/2 clinical trial, which is designed to evaluate 5F9 in patients with DLBCL and indolent lymphoma, including FL. Forty Seven expects to announce updated data in 2019. Forty Seven is also evaluating 5F9 in five additional clinical studies as both monotherapy and in combination in patients with solid tumors, acute myeloid leukemia, ovarian cancer and colorectal carcinoma.
“We are encouraged by the publication of this manuscript in the NEJM, which is among the first clinical data with a CD47-targeting antibody to be published in a major medical journal,” said
5F9 is a monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPα receptor on macrophages, thus blocking the “don’t eat me” signal used by cancer cells to avoid being ingested by macrophages.
Forward Looking Statements:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the advancement and clinical development of 5F9; the potential of 5F9 as a safe and efficacious treatment option for patients with
For journalist inquiries please contact
For investor inquiries please contact
Source: Forty Seven, Inc.